Batten Disease Market Segmentation:
- By Treatment Type
- Enzyme Replacement Therapy
- Gene Therapy
- Small Molecule Drugs
- Stem Cell Therapy
- Others
- By Disease Type
- CLN1 - infantile onset
- CLN2 - late infantile onset
- CLN3 - juvenile onset
- CLN4 - adult onset
- CLN5
- CLN6
- Others
- By End User
- Hospitals
- Specialty Clinics
- Research Institutes
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
- By Regions
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- Israel
- South Africa
- North Africa
- Central Africa
- Rest of the Middle East
Frequently Asked Questions
The Batten disease market was valued at USD 317.5 million in 2023.
Increasing research and development, advances in genetic testing and gene therapy, high unmet need, special regulatory status for orphan drugs.
Increasing R&D investments, advances in gene therapy and gene editing, specialty drug incentives, and high unmet need.
Rare disease, small patient population, high cost of therapies, reimbursement challenges.
BioMarin, Sarepta Therapeutics, Amicus Therapeutics, REGENXBIO, Evotec.
The market is expected to grow at a CAGR of 12.7% from 2023-2031 to reach USD 733.3 million by 2031.
Increasing R&D investments, advances in gene therapy and diagnostics, favorable regulations, high unmet need.